BiomX Inc. HLSQ
0.53
0.00
0.00%
as of 25 Sep
- Market cap
- $1.5M
- P/E
- 0.0×
Follow HLSQ
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
+8 more quarters Free account |
P/S ratio |
0.00 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(3.07) | — | — | — | |
P/B ratio |
0.32 | — | — | — | |
Price to Tangible BV |
0.00 | — | — | — | |
EV/Sales |
0.00 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(0.24) | — | — | — | |
EV/FCF |
(0.24) | — | — | — | |
Quick Ratio |
0.09 | 0.48 | 0.78 | 1.51 | |
Current Ratio |
0.24 | 1.24 | 0.87 | 1.70 | |
Net Debt/EBITDA |
(0.14) | 0.90 | 0.30 | 1.08 | |
Debt/Assets |
4.77% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.08 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.31 | 0.28 | 0.33 | 0.78 | |
Capex/Depreciation |
(0.40) | — | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
38.55% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,621.39% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.90 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,200.90% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(2.27) | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(5,731.33%) | — | — | — | |
Free Cash Flow Yield |
(504.27%) | — | — | — | |
Revenue per Share |
0.32 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.13) | (20.79) | (26.89) | (43.48) | |
Capex per Share |
0.00 | 0.00 | 0.01 | (0.01) | |
Free Cash Flow per Share |
(1.14) | (20.79) | (26.89) | (43.49) | |
Cash per Share |
0.55 | 4.49 | 30.38 | 47.87 | |
Shareholders Equity per Share |
17.09 | (3.38) | (7.98) | 63.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.09 | (3.38) | (7.98) | 63.47 | |
Free Cash Flow |
(1.17) | (5.41) | (4.38) | (7.18) | |
Working Capital |
(7.76) | 0.60 | (0.80) | 3.64 | |
Capital Expenditures |
0.00 | — | 0.00 | 0.00 | |
Net Current Asset Value |
(8.15) | (1.09) | (1.51) | (6.82) | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.01 | — | 0.00 | 0.00 | |
Net Profit Margin |
(1,136.14%) | 0.00% | 0.00% | 0.00% | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Receivables |
0.45 | — | — | — | |
Average Payables |
1.54 | 1.20 | 2.50 | 2.14 | |
Average Assets |
33.12 | 24.45 | 24.51 | 43.07 | |
Average Common Equity |
5.81 | (6.82) | (7.21) | 5.56 |
Columns are period end dates